We mine massive multi-dimensional datasets to identify targetable nuances in the genetic code unique to different cell types. Brain vs lung. Malignant vs non-maglinant. Epithelial vs endothelial.
We insert these signatures into the designer mRNA to target specific cells. Hyperselective translation activates malignant cells to make cancer-fighting proteins. Other cells can be activated to make health-promoting ones.
We control the designer mRNA’s journey into specific cells within target tissue using proprietary lipid nanoparticles that evade default accumulation in the liver.